Loading…
← CockpitCompetitor Analysis › WVE Wave Life Sciences Ltd.Open in the cockpit ↗

Wave Life Sciences Ltd.WVECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 8
Mkt cap
$546M
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$9.81M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$2.77
1D-2.5%
1W-19.0%
1M-19.0%
3M-47.2%
6M-55.2%
YTD-83.7%
1Y-61.3%
ATR %8.3%
Beta1.46
52w lowhigh87.2% off high

What Wave Life Sciences does

Employees: 317

Wave Life Sciences at a glance

Size Wave Life Sciences (WVE) is a United States Health Care company (Biotechnology) with a market value of $546M, the 2609th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.77 on 18 Nov 2026.

Performance Over six months the shares fell 55.2%, against -17.0% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.

Growth Revenue fell 35.1% over the last twelve months (peer median +7.5%); the operating margin is -320.9% (peer median -49.9%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 6.2× (2nd cheapest of 17).

Short interest Short interest is 10.5% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 83WVE 43
Six months, rebased to 100: Wave Life Sciences against the median of its 20 peers (local-currency closes).

Wave Life Sciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$70.9M$42.7M$108M$113M$3.65M
Revenue growth—-61%-4%+3,005%—
Gross profit$61.7M$33.9M$99.6M$104M-$6.46M
EBITDA-$218M-$207M-$102M-$58.8M-$153M
Net income-$211M-$204M-$97.0M-$57.5M-$162M
Free cash flow-$206M-$188M-$152M-$20.5M-$129M
Capital expenditure$1.33M$718,000$938,000$1.11M$1.36M
Total debt$43.3M$17.8M$25.4M$32.1M$37.6M

Quarterly statements and history in the cockpit →

Wave Life Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%CLYM1521300871SANA300404GNFT1672300318FDMT688639SRZN6586CBIOWVE6-month return →1-month return →
Up and to the right = strong over both horizons. Wave Life Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+20,000%+40,000%+60,000%+80,000%0×2,500×5,000×7,500×15213008711672FDMT6586WVERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wave Life Sciences is the large dot.

Wave Life Sciences competitors and peer comparison

How Wave Life Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wave Life Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureWVEPeer medianRank in peer set
1-month return-19.0%-14.3%6th lowest of 21
6-month return-55.2%-17.0%2nd lowest of 19
Distance from 52-week high-87.2%-47.6%lowest of 21
Revenue growth (TTM)-35.1%+7.5%3rd lowest of 16
Operating margin-320.9%-49.9%6th lowest of 17
EV / Sales2.2×6.2×2nd cheapest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a

Questions

Which companies are Wave Life Sciences's closest peers?
The cockpit's peer set: Climb Bio (CLYM), Frontage (1521.HK), Hvsen Biotechnology (300871.SZ), Sana Biotechnology (SANA), Boji Medical Technology (300404.SZ), Genfit (GNFT.PA), Ascletis Pharma (1672.HK), Beijing Bohui Innovation Biotechnology (300318.SZ).
Is Wave Life Sciences expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 6.2×, 2nd cheapest of 17 in its peer set.
How has Wave Life Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned -55.2% against -17.0% for the median peer; over one year -61.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.